TBK1 and Insulin resistance: Our previous studies demonstrated that inhibition of IKK-ε/TBK1 with the dual-specificity inhibitor amlexanox improved catecholamine and insulin resistance, and resulted in significant weight loss and reversal of metabolic disease in obese mice, but had no effect on normal-chow fed mice in which the kinases are not elevated8, 13.